A Phase II study to evaluate the efficacy and safety of PTK787 [vatalanib] in patients with metastatic cutaneous melanoma [malignant melanoma]
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2015
At a glance
- Drugs Vatalanib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 26 Mar 2009 Bayer Schering Pharma added as trial sponsor as reported by United Kingdom Clinical Research Network.
- 26 Mar 2009 New source identified and integrated (United Kingdom Clinical Research Network).
- 04 May 2008 Status changed from recruiting to in progress according to clinicaltrials.gov record.